GlassScriptPhysician profile
Ronald L Jackson
NPI 1982816674
$2,452.84
in general payments reported to CMS, 2019-2025
11 companies · $371 in 2025
The $371 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $61.33 · 2021: $181 · 2022: $593 · 2023: $671 · 2024: $340 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,382.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $604.81 | 2019-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $540.09 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Lundbeck LLC | $282.15 | 2022-2024 | Abilify Maintena |
| Indivior INC. | $274.96 | 2021-2023 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $219.75 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $179.19 | 2019-2025 | Invega Sustenna |
| Bioxcel Therapeutics, INC. | $91.02 | 2023-2024 | Igalmi |
| Neurocrine Biosciences, INC. | $88.20 | 2023-2024 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $80.16 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $67.27 | 2024 | Uzedy |
| Sunovion Pharmaceuticals INC. | $25.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.